RxDoctor Payments Data

Antonio Barksdale, MD

Family Medicine · Forney, TXNPI 1346478336

Payments from drug & device makers

$6,681in general payments, 2019–2025

Across 384 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$856
  • Pfizer$480
  • Lilly USA, LLC$453
  • Abbott$432
  • AstraZeneca$343
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,681 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$60,388
Medicare patients
184
Services billed
2,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$117,637
JardianceEmpagliflozin87$106,506
EliquisApixaban65$63,753
TrulicityDulaglutide35$63,412
FarxigaDapagliflozin Propanediol49$54,275
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$49,783
MounjaroTirzepatide21$38,793
LinzessLinaclotide11$13,379
Atrovent HfaIpratropium Bromide16$9,350
Tresiba Flextouch U-100Insulin Degludec12$7,860
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$6,662
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$6,597
Albuterol Sulfate HfaAlbuterol Sulfate113$2,838
Atorvastatin Calcium359$2,401
Estradiol28$2,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,052$117,63762 claims
Boehringer IngelheimJardiance$226$106,50687 claims
Lilly USA, LLCTrulicity, Mounjaro$453$102,20556 claims
PfizerEliquis$480$63,75365 claims
AstraZenecaFarxiga$343$54,27549 claims
GSKTrelegy Ellipta$157$49,78351 claims
AbbVieLinzess, Synthroid$856$14,32626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Forney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →